Benefits, Limitations, and Harm of Local Excision for Rectal Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To the Editor:
Major advances in surgical and medical oncology have improved treatment strategies and survival for patients with solid cancers over the last years. Currently, efforts for various cancers including colorectal, stomach, breast, and other tumors have been focused on how to achieve both local control by appropriate surgery alone or plus chemoradiotherapy1–4 and personalized adjuvant systemic treatment through molecular and genetic biomarkers.5–9
With the aim to improve quality of life (QOL), local excision and minimal access surgery, such as laparoscopic and robotic surgery,10 are increasingly used in clinical practice. However, what is the potential harm risked by less extensive surgery, particularly in the absence of randomized controlled trials? What does better QOL mean if there is an increased risk of local and nodal recurrence that may also result in increased mortality?
In a recent article, Borschitz et al. report on local excision after neoadjuvant chemoradiotherapy (n
- Enker WE, Thaler HT, Cranor ML, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181:335–46.
- Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107. CrossRef
- Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1.
- Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 366:2087–106.
- Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007; 6:308–12.
- Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197. CrossRef
- Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39. CrossRef
- Liakakos T, Roukos DH. More controversy than ever—Challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008 Jan 23 [Epub ahead of print] (DOI: 10.1245/s10434-007-9798-5)
- Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90. CrossRef
- Baik SH, Lee WJ, Rha KH, et al. Robotic total mesorectal excision for rectal cancer using four robotic arms. Surg Endosc 2007 Nov 20 [Epub ahead of print]
- Borschitz T, Wachtlin D, Möhler M, et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008; 15:712–20. CrossRef
- Roukos DH, Fatouros M, Tsianos E, et al. Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification? Nat Clin Pract Oncol 2006; 3:656–7. CrossRef
- Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919–32. CrossRef
- Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9:607–9. CrossRef
- Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3.
- Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007; 245:873–9. CrossRef
- Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6; author reply 1556. CrossRef
- Fatouros M, Baltoyiannis G, Roukos DH. The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women with BRCA1/2 Mutations. Ann Surg Oncol 2008; 15:21–33. CrossRef
- Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004; 11:1030–4. CrossRef
- Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21. CrossRef
- Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005; 5:737–45. CrossRef
- Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994; 3:115–25. CrossRef
- Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9. CrossRef
- Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5. CrossRef
- Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84:1602–9. CrossRef
- Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11:727–30. CrossRef
- Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59–62. CrossRef
- Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl1998; 80:16–24.
- Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7:253–5. CrossRef
- Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9. CrossRef
- Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46–56. CrossRef
- Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998; 123:573–8. CrossRef
- Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26:243–55. CrossRef
- Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol 2008; 86:139–41. CrossRef
- Benefits, Limitations, and Harm of Local Excision for Rectal Cancer
Annals of Surgical Oncology
Volume 15, Issue 9 , pp 2628-2629
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors